New pill targets brain tumors with IDH mutations

NCT ID NCT02481154

Completed Disease control Sponsor: Institut de Recherches Internationales Servier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a cure, it aims to control tumor growth by targeting the mutated IDH pathway.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
MD Anderson Cancer Center

Houston, Texas, 75390, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
UCLA Oncology Center

Los Angeles, California, 90024, United States
UT Southwestern Medical Center

Dallas, Texas, 77030, United States
University of California San Francisco

San Francisco, California, 94143, United States
University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.